Skip To Main Content
Bart Fevery on Muck Rack

Bart Fevery

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bart

Contact Bart, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

siRNA daplusiran/tomligisiran and DNA vaccine JNJ-64300535 in NA-suppressed chronic hepatitis B: the OSPREY study

|
By Stefan Bourgeois, María Buti, Edward J Gane, Kosh Agarwal, Ewa Janczewska, Yao-Chun Hsu, Pietro Lampertico, Joaquin Cabezas, Gloria Kim, Leen Slaets, Heather Davis, Dessislava Dimitrova, Joris Vandenbossche, Alan Harrison, Simon Verheijden, Michael Biermer, Maurizia Rosanna Brunetto, Adam Bakala, Bart Fevery, Ewoud De Troyer, Pieter Van Remoortere, Marjolein Crabbe, An De Creus
| Nature Verified
Abstract OSPREY was a single-arm, open-label, phase 1b study that assessed whether reduction of viral antigens by the small-interfering RNA daplusiran/tomligisiran (DAP/TOM) could enhance HBV-specific T-cell and/or HBsAg responses to the DNA vaccine JNJ-64300535 (JNJ-0535) in participants with virologically suppressed, HBeAg-negative chronic hepatitis B. All participants received DAP/TOM (200 mg, Q4W) for 24 weeks and 4 doses of JNJ-0535 from Week (W)14 to W26.
Open in Who Shared Issue with article?
See all 1 articles